Kebayoran Pharma is primarily engaged in pharmaceuticals activity. Its headquarters is located in Dki Jakarta. The company was founded in 1967. Kebayoran Pharma was established by Dr. Hadi Santoso and has grown to become a significant player in the Indonesian pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and health supplements. As a primary business line, Kebayoran Pharma is involved in the production of generic drugs, while its secondary business line includes the distribution of medical devices and healthcare products. The company operates several branches across Indonesia, with a strong presence in major cities such as Surabaya, Bandung, and Medan. Kebayoran Pharma's product portfolio includes well-known brands such as MedicaCare and VitaHealth, which are popular among healthcare professionals and consumers alike. The company has also expanded its operations internationally, exporting its products to several countries in Southeast Asia and the Middle East. In collaboration with international pharmaceutical companies, Kebayoran Pharma engages in joint ventures to enhance its research and development capabilities. The company is a member of the Indonesian Pharmaceutical Association and actively participates in industry events and forums. With a commitment to improving public health, Kebayoran Pharma aims to provide high-quality, affordable healthcare solutions. The company's vision is to be a leader in the pharmaceutical industry by continuously innovating and expanding its product offerings to meet the evolving needs of the healthcare sector.
Headquarters
RT 009 RW 006
Central Jakarta; Jakarta;
Postal Code: 10610
Contact Details: Purchase the PT Kebayoran Pharma report to view the information.
Website: http://www.kebayoranpharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service